Mesonephric adenocarcinomas of the uterine cervix and corpus: HPV-negative neoplasms that are commonly PAX8, CA125, and HMGA2 positive and that may be immunoreactive with TTF1 and hepatocyte nuclear factor 1-β

American Journal of Surgical Pathology

Volumn 36, Issue 6, 2012, Pages 799-807

  Kenny, Sarah L ^a   McBride, Hilary A ^a   Jamison, Jackie ^b   Glenn McCluggage, W ^a  

^a ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^b ANTRIM AREA HOSPITAL   (United Kingdom)

Author keywords

Cervix; HPV; Immunohistochemistry; Mesonephric adenocarcinoma

Indexed keywords

CA 125 ANTIGEN; DNA BINDING PROTEIN; HEPATOCYTE NUCLEAR FACTOR 1BETA; HIGH MOBILITY GROUP A2 PROTEIN; HNF1B PROTEIN, HUMAN; MEMBRANE PROTEIN; MUC16 PROTEIN, HUMAN; PAIRED BOX TRANSCRIPTION FACTOR; PAX8 PROTEIN, HUMAN; TTF1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ADENOCARCINOMA; AGED; ARTICLE; CELL NUCLEUS; FEMALE; HUMAN; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; ISOLATION AND PURIFICATION; MESONEPHROS; METABOLISM; METHODOLOGY; MIDDLE AGED; PAPILLOMA VIRUS; PATHOLOGY; UTERINE CERVIX TUMOR; UTERUS; VIROLOGY;

ADENOCARCINOMA; AGED; CA-125 ANTIGEN; CELL NUCLEUS; DNA-BINDING PROTEINS; FEMALE; HEPATOCYTE NUCLEAR FACTOR 1-BETA; HMGA2 PROTEIN; HUMANS; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; MESONEPHROS; MIDDLE AGED; NEOPLASM PROTEINS; PAIRED BOX TRANSCRIPTION FACTORS; PAPILLOMAVIRIDAE; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; UTERUS;

EID: 84861228222     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31824a72c6     Document Type: Article

References (42)

1. Al-Hussaini M, Stockman A, Foster H, et al. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing serous and ovarian endometrioid carcinoma. Histopathology. 2004;44:109-115. (Pubitemid 38296970)
2. Bague S, Rodriquez IM, Prat J. Malignant mesonephric tumors of the female genital tract. A clinicopathologic study of 9 cases. Am J Surg Pathol. 2004;28:601-607. (Pubitemid 38579561)
3. Brunner AH, Riss P, Heinz G, et al. Immunoexpression of PAX 8 in endometrial cancer: relation to high-grade carcinoma and p53. Int J Gynecol Pathol. 2011;30:569-575.
4. Chiesa-Vottero AG, Malpica A, Deavers MT, et al. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Int J Gynecol Pathol. 2007;26:328-333. (Pubitemid 46986071)
5. Clement PB, Young RH, Keh P, et al. Malignant mesonephric neoplasms of the uterine cervix. A report of eight cases, including four with a malignant spindle cell component. Am J Surg Pathol. 1995;19:1158-1171.
6. Dettmer M, Kim TE, Jung CK, et al. Thyroid transcription factor-1 expression in colorectal adenocarcinomas. Pathol Res Pract. 2011; 207:686-690.
7. Gattas GJ, Quade BJ, Nowak RA, et al. HMGIC expression in human adult and fetal tissues and in uterine leiomyomata. Genes Chromosomes Cancer. 1999;25:316-322. (Pubitemid 29326137)
8. Goldstein NS, Uzieblo A. WT-1 immunoreactivity in uterine papillary serous carcinoma is different from ovarian serous carcinomas. Am J Clin Pathol. 2002;117:541-545. (Pubitemid 34823682)
9. Hashi A, Yuminamochi T, Murata S-I, et al. Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium and peritoneum. Int J Gynecol Pathol. 2003;22:374-377. (Pubitemid 37152988)
10. Hee JA, Kim KR, Kim IS. Prevalence of human papilloma virus DNA in various histological subtypes of cervical adenocarcinoma: a population-based study. Mod Pathol. 2005;18:528-534. (Pubitemid 40478116)
11. Hirschowitz L, Ganesan R, W.G. McCluggage. WT1 p53 and hormone receptor expression in uterine serous carcinoma. Histopathology. 2009;55:478-482.
12. Houghton O, Jamison J, Wilson R, et al. P16 immunoreactivity in unusual types of cervical adenocarcinoma does not reflect human papillomavirus infection. Histopathology. 2010;57:342-350.
13. Kobel M, Kalloger SE, Carrick J, et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol. 2009;33:14-21.
14. Kubba LA, McCluggage WG, Liu J, et al. Thyroid transcription factor-1 expression in ovarian epithelial neoplasms. Mod Pathol. 2008;21:485-490. (Pubitemid 351441040)
15. Laury AR, Hornick JL, Perets R, et al. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol. 2010;34:627-635.
16. Laury AR, Perets R, Piao H, et al. A Comprehensive Analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol. 2011;35:816-826.
17. Mahajan A, Liu Z, Gellert L, et al. HMGA2: a biomarker significantly overexpressed in high-grade ovarian serous carcinoma. Mod Pathol. 2010;23:673-681.
18. Marquette A, Moerman P, Vergote I, et al. Second case of uterine mesonephric adenocarcinoma. Int J Gynecol Cancer. 2006;16: 1450-1454. (Pubitemid 43886786)
19. McCluggage WG. WT1 is of value in ascertaining the site of origin of serous carcinomas within the female genital tract. Int J Gynecol Pathol. 2004;23:97-99. (Pubitemid 38391767)
20. McCluggage WG, Connolly L, McBride HA. HMGA2 is a sensitive but not specific immunohistochemical marker of vulvovaginal aggressive angiomyxoma. Am J Surg Pathol. 2010;34:1037-1042.
21. McCluggage WG, Connolly LE, McBride HA, et al. HMGA2 is commonly positive in uterine serous carcinomas and is a useful adjunct to diagnosis. Histopathology. 2012. [Epub ahead of print].
22. McCluggage WG, Kennedy K, Busam KJ. An immunohistochemical study of cervical neuroendocrine carcinomas: neoplasms which are commonly TTF1 positive and which may express CK20 and p63. Am J Surg Pathol. 2010;34:525-532.
23. McCluggage WG, Oliva E, Herrington CS, et al. CD10 and calretinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: CD10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial stroma. Histopathology. 2003;43:144-150. (Pubitemid 36963158)
24. Nonaka D, Chirboga L, Soslow RA. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol. 2008;32:1566-1571.
25. Oliva E. CD10 expression in the female genital tract: does it have useful diagnostic implications? Adv Anat Pathol. 2004;11:310-315.
26. O'Neill CJ, McCluggage WG. p16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol. 2006;13:8-15. (Pubitemid 44357144)
27. Ordi J, Nogales FF, Palacin A, et al. Mesonephric adenocarcinoma of the uterine corpus: CD10 expression as evidence of mesonephric differentiation. Am J Surg Pathol. 2001;25:1540-1545. (Pubitemid 33096970)
28. Ordi J, Ramagosa C, Tavassoli FA. CD10 expression in epithelial tissues and tumors of the gynecologic tract. Am J Surg Pathol. 2003;27:178-186.
29. Ozcan A, Liles N, Coffey D, et al. PAX2 and PAX8 expression in primary and metastatic Mü llerian epithelial tumors: a comprehensive comparison. Am J Surg Pathol. 2011;35:1837-1847.
30. Park KJ, Kiyokawa T, Soslow RA, et al. Unusual endocervical adenocarcinomas: an immunohistochemical analysis with molecular detection of human papillomavirus. Am J Surg Pathol. 2011;35: 633-646.
31. Pirog EC, Kleter B, Olgac S, et al. Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am J Pathol. 2000;157:1055-1062.
32. Rogalla P, Drechsler K, Frey G, et al. HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors. Am J Pathol. 1996;149:775-779. (Pubitemid 26334162)
33. Shimizu M, Toki T, Takagi Y, et al. Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol. 2000;19:158-163. (Pubitemid 30212153)
34. Siami K, McCluggage WG, Ordonez NG, et al. Thyroid transcription factor-1 expression in endometrial and endocervical adenocarcinomas. Am J Surg Pathol. 2007;31: 1759-1763. (Pubitemid 350287575)
35. Silver SA, Devouassoux-Shisheboran M, Mezzetti TP, et al. Mesonephric adenocarcinomas of the uterine cervix: a study of 11 cases with immunohistochemical findings. Am J Surg Pathol. 2001; 25:379-387. (Pubitemid 32174207)
36. Tong GX, Memeo L, Colarossi C, et al. PAX8 and PAX2 immunostaining facilitates the diagnosis of primary epithelial neoplasms of the male genital tract. Am J Surg Pathol. 2011;35: 1473-1483.
37. Tsuchiya A, Sakamoto M, Yasuda J, et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol. 2003;163: 2503-2512. (Pubitemid 37466491)
38. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19. (Pubitemid 29406813)
39. Wei JJ, Wu J, Luan C, et al. HMGA2: a potential biomarker complement to P53 for detection of early-stage high-grade papillary serous carcinoma in fallopian tubes. Am J Surg Pathol. 2010;34: 18-26.
40. Yamamoto S, Tsuda H, Aida S, et al. Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. Hum Pathol. 2007;38:1074-1080. (Pubitemid 46899152)
41. Yemelyanova A, Ji H, Iem Shih, et al. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am J Surg Pathol. 2009;33: 1504-1514.
42. Young RH, Clement PB. Endocervical adenocarcinoma and its variants: their morphology and differential diagnosis. Histopathology. 2002;41:185-207. (Pubitemid 35013941)